Target Information

Target General Infomation
Target ID
T27186
Former ID
TTDC00176
Target Name
Placenta growth factor
Gene Name
PGF
Synonyms
PlGF-131; PGF
Target Type
Clinical Trial
Disease Macular degeneration [ICD9: 362.5; ICD10: H35.3]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
Growth factor active in angiogenesisand endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.
BioChemical Class
Growth factor
Target Validation
T27186
UniProt ID
P49763
Sequence
MPVMRLFPCFLQLLAGLALPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALERLVD
VVSEYPSEVEHMFSPSCVSLLRCTGCCGDENLHCVPVETANVTMQLLKIRSGDRPSYVEL
TFSQHVRCECRHSPGRQSPDMPGDFRADAPSFLPPRRSLPMLFRMEWGCALTGSQSAVWP
SSPVPEEIPRMHPGRNGKKQQRKPLREKMKPERCGDAVPRR
Drugs and Mode of Action
Drug(s) RO-5323441 Drug Info Phase 2 Solid tumours [523948]
R7334 Drug Info Phase 1 Macular degeneration [522356]
SFLT-01 Drug Info Phase 1 Macular degeneration [522879]
Inhibitor 2-Methyl-2,4-Pentanediol Drug Info [551393]
RO-5323441 Drug Info [549755]
Modulator SFLT-01 Drug Info [531341]
Pathways
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Focal adhesion
Pathways in cancer
NetPath Pathway TSH Signaling Pathway
Pathway Interaction Database VEGFR1 specific signals
Reactome VEGF ligand-receptor interactions
VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Focal Adhesion
Signaling by VEGF
References
Ref 522356ClinicalTrials.gov (NCT00702494) Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours. U.S. National Institutes of Health.
Ref 522879ClinicalTrials.gov (NCT01024998) Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). U.S. National Institutes of Health.
Ref 523948ClinicalTrials.gov (NCT01622764) 89Zr-RO5323441 PET Imaging in Glioblastoma. U.S. National Institutes of Health.
Ref 531341sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
Ref 549755RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 551607Clinical pipeline report, company report or official report of Roche (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.